Kaplan‐Meier curves. (A) PFS for cases receiving frontline rituximab‐containing regimens vs treatments not containing rituximab: median PFS, NR; 95% CI, 11.0 months‐NR vs median PFS, 11.0 months; 95% CI, 6.1‐32.8 (P = .05). (B) OS for cases receiving frontline rituximab‐containing regimens vs those not containing rituximab: median OS, NR; 95% CI, 21.7 months‐NR vs median OS, 64 months; 95% CI, 9.5‐NR (P = .32).